Evidence map›Paper›PMID 23760497›Full record

ArticleCancer biology & therapy2013

PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia.

Nora Barboza, Svetlana Minakhina, Daniel J Medina, Binaifer Balsara, Sonya Greenwood, Lien Huzzy, Arnold B Rabson, Ruth Steward, Dale G Schaar

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. [Pregnane X receptor promotes programmed cell death protein 4 expression in HepG2 cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.International journal of clinical and experimental pathology · 2015
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Nora BarbozaUniversity of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Svetlana Minakhina
Daniel J Medina
Binaifer Balsara
Sonya Greenwood
Lien Huzzy
Arnold B Rabson
Ruth Steward
Dale G Schaar
Rutgers Cancer Institute of New JerseyAckerman Institute for the Family · USJohnson University · USBrunswick (United States) · USNovartis (Switzerland) · CH

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
NCI NIH HHS P30 CA072720
6 · The paper itself

Abstract

PDCD2 is an evolutionarily conserved eukaryotic protein with unknown function. The Drosophlia PDCD2 ortholog Zfrp8 has an essential function in fly hematopoiesis. Zfrp8 mutants exhibit marked lymph gland hyperplasia that results from increased proliferation of partially differentiated hemocytes, suggesting Zfrp8 may participate in cell growth. Based on the above observations we have focused on the role of PDCD2 in human cancer cell proliferation and hypothesized that aberrant PDCD2 expression may be characteristic of human malignancies. We report that PDCD2 is highly expressed in human acute leukemia cells as well as in normal hematopoietic progenitors. PDCD2 knockdown in cancer cells impairs their proliferation, but not viability relative to parental cells, supporting the notion that PDCD2 overexpression facilitates cancer cell growth. Prospective analysis of PDCD2 in acute leukemia patients indicates PDCD2 RNA expression correlates with disease status and is a significant predictor of clinical relapse. PDCD2's role in cell proliferation and its high expression in human malignancies make it an attractive, novel potential molecular target for new anti-cancer therapies.

Indexed as

Cell ProliferationApoptosis Regulatory ProteinsBiomarkers, TumorCell Line, TumorGene ExpressionGene Knockdown TechniquesHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteNeoplasm Recurrence, LocalProspective StudiesRNA, MessengerApoptosis Regulatory ProteinsBiomarkers, TumorPDCD2 protein, humanRNA, Messengeracute lymphoblastic leukemiaacute myelogenous leukemiacellular proliferationhematopoietic stem cellsPDCD2

Identifiers

PMID23760497
PMCPMC3813571
OpenAlexW2003578820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.